血清Her-2-ECD、TPS水平与Her-2阳性乳腺癌曲妥珠单抗敏感性的相关性  

Correlation Between Serum HER-2-ECD and TPS Levels and Sensitivity to Trastuzumab in Her-2 Positive Breast Cancer

作　　者：陈柯 牛萍[1] 王芳[1] CHEN Ke;NIU Ping;WANG Fang(The First People's Hospital of Nanyang,Nanyang,473000)

机构地区：[1]河南省南阳市第一人民医院,473000

出　　处：《实用癌症杂志》2025年第1期9-12,共4页The Practical Journal of Cancer

摘　　要：目的探讨血清Her-2-ECD、TPS水平与Her-2阳性乳腺癌曲妥珠单抗敏感性的关系。方法选取Her-2阳性乳腺癌患者100例,均接受曲妥珠单抗治疗,根据RECIST1.1标准评价疗效,将CR+PR纳入敏感组,SD+PD纳入耐药组。同时期选取健康人群30名纳入对照组。比较3组血清Her-2-ECD、TPS水平。分析Her-2-ECD、TPS水平与乳腺癌患者临床病理参数和疗效的关系。结果CR+PR共79例,SD+PD共21例。3组血清Her-2-ECD、TPS水平比较,差异有统计学意义(P<0.05),其中耐药组血清Her-2-ECD、TPS水平最高,敏感组次之,对照组最低。不同组织学分级、肿瘤转移部位数量患者血清Her-2-ECD、TPS水平比较,差异有统计学意义(P<0.05);不同年龄、月经状态、ECOG评分患者血清Her-2-ECD、TPS水平比较,差异无统计学意义(P>0.05)。血清Her-2-ECD、TPS水平联合预测靶向治疗疗效灵敏度84.69%、特异度78.49%、AUC 0.841,均较单一检测更高(P<0.05)。耐药组中血清Her-2-ECD>41.55 ng/ml、血清TPS>118.47 U/L的患者占比均高于敏感组(P<0.05)。结论血清Her-2-ECD、TPS水平与Her-2阳性乳腺癌患者对曲妥珠单抗治疗的敏感性具有一定关系,联合检测可以提高对靶向治疗疗效的预测能力。Objective To investigate the relationship between serum HER-2-ECD and TPS levels and the sensitivity to trastuzumab in Her-2 positive breast cancer.Methods A total of 100 patients with Her-2 positive breast cancer were selected and treated with trastuzumab.The efficacy was evaluated according to RECIST1.1 criteria.At the same time,30 healthy people were selected as the control group.The serum levels of Her-2-ECD and TPS were compared among the three groups.The relationship between the clinical pathological parameters and efficacy of breast cancer patients was analyzed.Results A total of 79 patients achieved CR+PR,and 21 patients achieved SD+PD.There were significant differences in the levels of serum Her-2-ECD and TPS among the three groups(P<0.05).The levels of serum Her-2-ECD and TPS in the resistant group were the highest,followed by the sensitive group,and the lowest in the control group.There were significant differences in serum Her-2-ECD and TPS levels among patients with different histological grades and the number of tumor metastasis sites(P<0.05),but there were no significant differences in serum Her-2-ECD and TPS levels among patients with different ages,menstrual status,and ECOG scores(P>0.05).Serum Her-2-ECD and TPS levels combined to predict the efficacy of targeted therapy had a sensitivity of 84.69%,a specificity of 78.49%,and an AUC of 0.841,which were higher than those of single detection(P<0.05).The proportion of patients with serum Her-2-ECD>41.55ng/ml and serum TPS>118.47U/L in the drug-resistant group was higher than that in the sensitive group(P<0.05).Conclusion Serum Her-2-ECD and TPS levels are related to the sensitivity of trastuzumab in HER-2-positive breast cancer patients.Combined detection can improve the predictive ability of targeted therapy response.

关 键 词：乳腺癌 HER-2阳性 Her-2-ECD TPS 曲妥珠单抗 敏感性 

分 类 号：R737.9[医药卫生—肿瘤]